PRDX4

Across TCGA pan-cancer cohorts, PRDX4 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of PRDX4’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where PRDX4 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types PRDX4 is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

CCRCC, LSCC, and LUAD are the cancer types where PRDX4 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PRDX4 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	IV	+1.156	<.001	12	view →
LSCC	Female	II,III,IV	+0.707	<.001	9	view →
LUAD	Male	III,IV	+0.661	<.001	9	view →
COAD	Male	All	+0.302	<.001	9	view →
HNSC	All	All	+0.204	.013	9	view →
PDAC	Female	All	−1.447	<.001	8	view →
OV	All	All	+0.537	.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

PRDX4–CCRCC

Open the CCRCC breakdown →